Skadden secured a summary judgment ruling for Pfizer Inc in a suit filed in the U.S. District Court for the District of Massachusetts by two insurance companies seeking over $200 million in damages (to be trebled under RICO) over Pfizer's alleged "off-label" marketing of the epilepsy drug Neurontin. On January 8, U.S. District Judge Patti Saris ruled that both companies failed to present sufficient evidence that they had been forced to overpay for Neurontin prescriptions and dismissed their claims.
Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates